Benefits of CDP-Choline (Citicoline)

Evidence-Based Benefits

• Attention and focus — McGlade et al. (2012) found that 250mg/day Cognizin citicoline significantly improved attention and psychomotor speed in healthy middle-aged adults after 28 days
• Memory enhancement — a 2021 systematic review of 14 clinical trials confirmed citicoline improves memory performance in both cognitively impaired and healthy populations
• Dopamine support — citicoline increases dopamine receptor density in the striatum and enhances dopamine synthesis, providing motivational and mood benefits beyond pure cholinergics
• Stroke recovery — the ICTUS trial and multiple meta-analyses support citicoline's use in acute ischemic stroke recovery, with European and Japanese medical guidelines recommending it as adjunct therapy
• Neuroprotection — citicoline stabilizes cell membranes by increasing phosphatidylcholine synthesis and reduces oxidative damage to neuronal tissue

What the Research Says

Citicoline has one of the strongest evidence bases among nootropic compounds. McGlade et al. (2012) demonstrated cognitive improvements in healthy adults at just 250mg/day. The large body of stroke recovery literature, including the ICTUS trial, has led to its inclusion in medical guidelines across Europe and Japan. A 2021 systematic review confirmed benefits across multiple cognitive domains. The Cognizin branded form has been the subject of the majority of supplement-focused clinical trials, ensuring consistent quality and dosing.

Related Conditions